Company intelligence / Profile preview
Eisai Co., Ltd.
Tokyo, Japaneisai.com ↗
- Ownership
- Public · 4523
- Employees
- ~10000
- Development stage
- Commercial
01
Overview
Eisai has multiple approved products including LEQEMBI for Alzheimer's disease, Fycompa for epilepsy, and Halaven for breast cancer and liposarcoma. The company continues to develop new treatments in neurology and oncology.
- Therapeutic areas
- OncologyCardiovascularNeurology
- Modalities
- Small moleculesmonoclonal antibodiesantibody-drug conjugates
- Industry
- Pharma
02
Drug pipeline
119 assets118 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $8.7B
- Total revenue
- $5.2B
- Enterprise value
- $8.4B
Beyond the preview
Go deeper on Eisai Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eisai Co., Ltd..